
FDA Accepts IND Application for ST-001 in Relapsed/Refractory SCLC
The FDA has approved an investigational new drug application (IND) for ST-001, a novel fenretinide phospholipid suspension, as an intravenous therapy for patients with relapsed/refractory small cell lung cancer (SCLC), according to a press release from …